115370 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)
  7. Center for Hematologic Malignancies (13263)
  8. Hematologic Malignancies, Division of (13087)
  9. Sloan Kettering Institute Postdocs (12936)
  10. Department of Pathology and Laboratory Medicine (12615)
Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Inhibition of toll-like receptor 4 (TLR4) promotes erythroid and myeloid differentiation in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)
    Meeting Abstract

    Fromowitz, A.; Aluri, S.; Lugo, J. D. G.; Rabinovich, E.; Ramachandra, N.; Aminov, S.; Sahu, S.; Mitchell, S. G.; Aggarwal, R.; Ajibade, O.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Clinical Factors but not somatic mutations predict for survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplant: Analysis of the North American myelofibrosis transplant outcome (NAMTO) study
    Meeting Abstract

    Ajufo, H.; Derkach, A.; Rampal, R. K.; Famulare, C.; Nemirovsky, D.; Chervin, J.; Ho, V.; Gupta, V.; Viswabandya, A.; Deeg, H. J.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Engraftment syndrome during autologous stem cell transplant in Hodgkin lymphoma patients treated with checkpoint inhibitors: A multi-center retrospective analysis
    Meeting Abstract

    Taranto, E.; Hwang, W. T.; Alfaro, M.; Surapaneni, A. S.; Gill, S. K.; Feldman, T.; Randall, M. P.; Spinner, M. A.; Furqan, F.; Shah, N. N.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Contemporary multiple myeloma treatment patterns among HCPs and concordance with expert recommendations: Analysis of an interactive online decision support tool
    Meeting Abstract

    Brandt, K. G.; Rosenthal, K.; Kumar, S. K.; Lentzsch, S.; Lonial, S.; Usmani, S. Z.; Quill, T. A.; Mikhael, J. R.
    Blood (2023)

    Fulltext@MSK | Save
  • Efficacy of brentuximab vedotin maintenance therapy following autologous stem cell transplantation in patients with relapsed/refractory classical Hodgkin lymphoma with and without pre-transplant exposure to novel agents
    Meeting Abstract

    Falade, A. S.; Redd, R. A.; Shah, H.; Baron, K.; Iyengar, S.; Desai, S. H.; Ansell, S. M.; Micallef, I.; Nedved, A.; Ganesan, N.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • ASC2ESCALATE: A US phase 2, open-label, single-arm, dose-escalation study of asciminib (ASC) monotherapy in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) as second-line (2L) and first-line (1L) treatment
    Meeting Abstract

    Atallah, E. L.; Mauro, M.; Sasaki, K.; Levy, M.; Koller, P. B.; Yang, D.; Laine, D.; Sabo, J.; Gu, E.; Cortes, J.
    Blood (2023)

    Fulltext@MSK | Save
  • Multicenter retrospective evaluation of treatment of high-risk acute promyelocytic leukemia (APL): Results from the Hematology Research Outcomes (HERO) Consortium
    Meeting Abstract

    Benitez, L.; Marx, K. R.; Buhlinger, K. M.; Clark, S. M.; Reid, J. H.; Rausch, C. R.; Gatwood, K. S.; Stump, S. E.; Shah, R.; Ciervo, J.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Manufacturing, characterization and anti-tumor activity of allogeneic CD19-CAR cytokine-induced killer (CIK) cells engineered with non-viral sleeping beauty transposon system and armored with IL-18
    Meeting Abstract

    Contreras-Ruiz, L.; Pace, B.; Kohnke, D. E.; Viruet, L.; Adams, M.; Krisko, J. F.; Leesnitzer, N.; Velie, M.; Tettamanti, S.; Pisani, I.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of elranatamab in Black patients with relapsed/refractory multiple myeloma (RRMM): A Subgroup analysis of the magnetismm studies
    Meeting Abstract

    Varshavsky-Yanovsky, A.; Jethava, Y.; Stevens, D. A.; Nooka, A. K.; Stiff, P. J.; Perez-Cruz, I.; Leip, E.; Lesokhin, A.
    Blood (2023)

    Fulltext@MSK | Save
  • Real-world patient profile and step-up dosing process of early initiators of teclistamab for multiple myeloma in US hospitals - An updated analysis using premier healthcare database
    Meeting Abstract

    Tan, C. R.; Kim, N.; Chinaeke, E.; Hester, L.; Fowler, J.; Gifkins, D.; Lin, D.; Walker, S.; Fu, A. Z.; Wu, B.
    Blood (2023)

    Fulltext@MSK | Save